SYLVIA FLOWER: Open Payments
NPI 1295709541 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,855 in 72 payments from 20 companies in 2025. Trend: 2023 $848 · 2024 $1,327 · 2025 $1,855
Food & beverage: $1,785Education: $70
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 14 | $342 |
| GlaxoSmithKline, LLC. | 9 | $203 |
| GENZYME CORPORATION | 5 | $202 |
| Novartis Pharmaceuticals Corporation | 7 | $142 |
| ARS Pharmaceuticals Operations, Inc. | 7 | $141 |
| CSL Behring | 5 | $134 |
| BioCryst US Sales Co., LLC | 3 | $98 |
| Regeneron Healthcare Solutions, Inc. | 3 | $90 |
| Blueprint Medicines Corporation | 2 | $85 |
| SANOFI-AVENTIS U.S. LLC | 1 | $70 |
Products named: DUPIXENT, TEZSPIRE, NUCALA, NEFFY, AYVAKIT, FASENRA, ORLADEYO, Rhapsido.
Industry payments across GA — which companies pay providers there.
